Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

[1]  M Maclure,et al.  Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. , 2001, American journal of epidemiology.

[2]  J. Iglehart.  Medicare and prescription drugs. , 2001, The New England journal of medicine.

[3]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[4]  S. Schneeweiss,et al.  On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. , 2001, Health policy.

[5]  J A Hanley,et al.  Adverse events associated with prescription drug cost-sharing among poor and elderly persons. , 2001, JAMA.

[6]  S. Horwitz,et al.  Physician gender and cesarean sections. , 2000, Journal of clinical epidemiology.

[7]  D. Rubin,et al.  Combining Propensity Score Matching with Additional Adjustments for Prognostic Covariates , 2000 .

[8]  J. Newhouse,et al.  The Medicare prescription drug benefit: how will the game be played? , 2000, Health affairs.

[9]  S. Suissa,et al.  Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[10]  D Y Lin,et al.  Methods for analyzing health care utilization and costs. , 1999, Annual review of public health.

[11]  Merlin C. Thomas,et al.  Increased thrombotic vascular events after change of statin , 1998, The Lancet.

[12]  K. Levit,et al.  National health expenditures in 1997: more slow growth. , 1998, Health affairs.

[13]  S. Schneeweiss,et al.  What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? , 1998, Health policy.

[14]  N. Kane.  Pharmaceutical cost containment and innovation in the United States. , 1997, Health policy.

[15]  P Grootendorst,et al.  Reference-based pricing (RBP) of prescription drugs. , 1997, The Canadian journal of cardiology.

[16]  J. Hallas.  Evidence of Depression Provoked by Cardiovascular Medication: A Prescription Sequence Symmetry Analysis , 1996, Epidemiology.

[17]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .

[18]  J. Buring,et al.  Ways of measuring rates of recurrent events , 1996, BMJ.

[19]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[20]  S. Goodman,et al.  The Use of Predicted Confidence Intervals When Planning Experiments and the Misuse of Power When Interpreting Results , 1994, Annals of Internal Medicine.

[21]  E H Wagner,et al.  A chronic disease score from automated pharmacy data. , 1992, Journal of clinical epidemiology.

[22]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[23]  James E. Veney,et al.  Evaluation and Decision Making for Health Services , 1991 .

[24]  M. Podgor,et al.  Compliance, bias, and power in clinical trials. , 1991, Biometrics.

[25]  L. Ried,et al.  The Effect of Drug Co-Payments on Utilization and Cost of Pharmaceuticals in a Health Maintenance Organization , 1990, Medical care.

[26]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[27]  D. Rubin,et al.  Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .

[28]  C E Reeder,et al.  The Effect of a Medicaid Drug Copayment Program on the Utilization and Cost of Prescription Services , 1984, Medical care.

[29]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[30]  Peter E. Kennedy,et al.  A Guide to Econometrics , 1980 .

[31]  M. Roemer,et al.  Copayments for Ambulatory Care: Penny-Wise and Pound-Foolish , 1975, Medical care.

[32]  C. Marra,et al.  Influence of the British Columbia reference drug program on hospital formularies: a survey of hospital pharmacy managers. , 2000, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[33]  P. McLaughlin.  Reference-based pricing of prescription drugs. , 1997, The Canadian journal of cardiology.

[34]  A. P. Boulet,et al.  Reference-based pricing in British Columbia: implications for cardiologists--an analysis. , 1997, The Canadian journal of cardiology.

[35]  Mclaughlin Pr.  Reference-based pricing of prescription drugs. , 1997 .

[36]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[37]  C. Hertzman,et al.  Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program. , 1993, Inquiry : a journal of medical care organization, provision and financing.

[38]  S B Soumerai,et al.  Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. , 1987, The New England journal of medicine.

[39]  C. E. Reeder,et al.  The differential impact of copayment on drug use in a Medicaid population. , 1985, Inquiry : a journal of medical care organization, provision and financing.

[40]  D. Makuc,et al.  Analysis of interrupted time series mortality trends: an example to evaluate regionalized perinatal care. , 1981, American journal of public health.